Zhang H - Search Results

1

Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors.

Xiao Z, Xue J, Gu WZ, Bui M, Li G, Tao ZF, Lin NH, Sowin TJ, Zhang H. Xiao Z, et al. Among authors: zhang h. Biomarkers. 2008 Sep;13(6):579-96. doi: 10.1080/13547500802063240. Biomarkers. 2008. PMID: 18671143

2

Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents.

Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S, Zhang H. Xiao Z, et al. Among authors: zhang h. J Biol Chem. 2003 Jun 13;278(24):21767-73. doi: 10.1074/jbc.M300229200. Epub 2003 Apr 3. J Biol Chem. 2003. PMID: 12676925 Free article.

3

Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint.

Chen Z, Xiao Z, Chen J, Ng SC, Sowin T, Sham H, Rosenberg S, Fesik S, Zhang H. Chen Z, et al. Among authors: zhang h. Mol Cancer Ther. 2003 Jun;2(6):543-8. Mol Cancer Ther. 2003. PMID: 12813133

4

A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.

Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H. Xiao Z, et al. Among authors: zhang h. Oncogene. 2005 Feb 17;24(8):1403-11. doi: 10.1038/sj.onc.1208309. Oncogene. 2005. PMID: 15608676

5

Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.

Xiao Z, Xue J, Semizarov D, Sowin TJ, Rosenberg SH, Zhang H. Xiao Z, et al. Among authors: zhang h. Int J Cancer. 2005 Jul 1;115(4):528-38. doi: 10.1002/ijc.20770. Int J Cancer. 2005. PMID: 15688426

6

1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities.

Wang GT, Li G, Mantei RA, Chen Z, Kovar P, Gu W, Xiao Z, Zhang H, Sham HL, Sowin T, Rosenberg SH, Lin NH. Wang GT, et al. Among authors: zhang h. J Med Chem. 2005 May 5;48(9):3118-21. doi: 10.1021/jm048989d. J Med Chem. 2005. PMID: 15857116

7

Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors.

Li G, Hasvold LA, Tao ZF, Wang GT, Gwaltney SL 2nd, Patel J, Kovar P, Credo RB, Chen Z, Zhang H, Park C, Sham HL, Sowin T, Rosenberg SH, Lin NH. Li G, et al. Among authors: zhang h. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2293-8. doi: 10.1016/j.bmcl.2006.01.028. Epub 2006 Jan 30. Bioorg Med Chem Lett. 2006. PMID: 16446090

8

Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.

Xiao Z, Xue J, Sowin TJ, Zhang H. Xiao Z, et al. Among authors: zhang h. Mol Cancer Ther. 2006 Aug;5(8):1935-43. doi: 10.1158/1535-7163.MCT-06-0077. Mol Cancer Ther. 2006. PMID: 16928813

9

Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.

Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Kovar P, Li G, Wang G, Tao ZF, Tong Y, Lin NH, Sham HL, Wang JY, Sowin TJ, Rosenberg SH, Zhang H. Chen Z, et al. Among authors: zhang h. Int J Cancer. 2006 Dec 15;119(12):2784-94. doi: 10.1002/ijc.22198. Int J Cancer. 2006. PMID: 17019715

10

Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.

Tao ZF, Li G, Tong Y, Chen Z, Merta P, Kovar P, Zhang H, Rosenberg SH, Sham HL, Sowin TJ, Lin NH. Tao ZF, et al. Among authors: zhang h. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4308-15. doi: 10.1016/j.bmcl.2007.05.027. Epub 2007 May 16. Bioorg Med Chem Lett. 2007. PMID: 17544271

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

129,352 results

Search Page

Filters